Lecanemab Extension Study for AD Offers Mixed Results : vima

The lecanemab open-label extension trial for AD showed no new safety signals, but the placebo roll-over group failed to show the gains seen in the experimental arm.

Related Keywords

Boston , Massachusetts , United States , Denver , Colorado , American , Marcelo Matiello , Michael Irizarry , Harvard Medical School , Alzheimer Disease Neuroimaging Initiative , American Academy Of Neurology , Eisai Ltd , American Academy , Clinical Dementia Rating , Disease Neuroimaging Initiative , Mass General Hospital , Alzheimer 039s Disease , Alzheimer Disease , Positron Emission Tomography , Pet , Get Scan , Et Positron Emission Tomography , Brain , Clinical Research , Clinical Trials , Linical Studies , Pre Clinical Trial , Double Blind Study , Double Blind Studies , Ingle Blind Study , Ingle Blind Studies , Dementia , Geriatrics , Elder Care , Geriatric Medicine , Older Adults , Seniors , Senior Citizens , Elderly , Hospitals ,